Q32 Bio will report topline 36-week results from Part B of its Phase 2a SIGNAL-AA clinical trial for bempikibart, a drug targeting severe alopecia areata, on July 13, 2026. The company will hold a conference call and webcast to discuss the data, which is important as bempikibart aims to offer a new treatment option for this autoimmune disease with limited therapies. Investors and interested parties can access the live event via Q32 Bio's website or phone. This update is a key milestone in Q32 Bio's development of innovative therapies for autoimmune conditions.
The BIP-110 Bitcoin fork has stalled after miners produced only two blocks in eight hours, while Bitcoin's main chain advanced by 48 blocks. This fork inherited Bitcoin's mining difficulty despite having very limited mining power, causing extremely s...
MARA Holdings secured $600 million in Bitcoin-backed loans by pledging 18,750 BTC, over half its Bitcoin treasury, to finance a new power-generation site aimed at supporting AI and high-performance computing. The loans, part of a $750 million facilit...
XRP is trading near $1.04, showing early signs of a possible macro bottom but still facing key support tests at $1.00. Analyst EGRAG Crypto highlights $1.00 as a critical support level that XRP must defend to avoid dropping to $0.70-$0.80, with $1.35...
Travelzoo has announced new exclusive travel deals for its Canadian Club Members, featuring discounted packages to destinations like Portugal, the Maldives, British Columbia, and Antigua. Offers include a $799 Portugal coastal getaway with flights, a...
US stock markets closed last week with strong gains, led by the Dow, Nasdaq, and S&P 500, all maintaining levels above their rising 52-week averages. Investors are closely watching upcoming inflation reports (CPI and PPI) and earnings from tech compa...
